Objectives: The study was designed to assess and compare the changes in the body mass index of patients on typical and atypical antipsychotics in a tertiary hospital in Nigeria.
Introduction
Evidence abounds that there is increasing global prevalence and trends of overweight among people of several nations and this poses a myriad of health consequences, reduced quality of life and poor drug compliance as well as an increased risk of premature illness and death latter in life [1, 2] . Excess adiposity is well documented as one of the principal health threats and is a major risk factor for type 2 diabetes, hypertension, cardiovascular and cerebrovascular disease [3] . The global nature of the obesity epidemic has been formally recognized by the World Health Organization in 1997 [4] . Weight gain is a well documented serious side effect of antipsychotic therapy and many studies have tried to assess the impact of the various types of antipsychotic on the weight of those taking them [5] [6] [7] . However, most of these studies were carried out in the developed world. There is a paucity of similar studies in the undeveloped world of which Nigeria is a part. It is also known that there is obvious genetic and racial differences in the cytochrome P450 drug metabolizing enzymes of Caucasians compared to non-Caucasians [8, 9] .
In the light of the foregoing, this study aims at evaluating the body mass index changes of patients on antipsychotic therapy in a tertiary hospital in Nigeria. The comparison between the typical and atypical antipsychotics was done. It is expected that results from this study will not only add to our knowledge about the pharmacodynamics of these medications but it will guide clinicians in prescribing them to patients and provide a reliable data which will enable health care policy makers enunciate more patient friendly policies with respect to making available the best medications.
Subjects and Method
This prospective cross-sectional study was conducted at the psychiatric clinic of the Madonna University Teaching Hospital over an eight month period, from February 2014-October 2014.
Instruments
For this study, the instruments used are as follows:-1. The Schedule for Clinical Assessment in Neuropsychiatry (SCAN), interview schedule, version 2.1
Socio-demographic questionnaire
The Schedule for Clinical Assessment in Neuropsychiatry (SCAN), interview schedule, version 2.1 is an excellent instrument for diagnosing psychiatric disorders based on the ICD 10 diagnostic criteria [10] . A questionnaire containing socio-demographic variables, prepared by the researchers was administered to each subject.
Procedure
Before the commencement of the study, approval of the ethical committee of the institution was sought and informed consent obtained from the subjects enlisted into the study. All psychiatric patients placed on antipsychotic treatment for the first time were included in the study while all those who have been on antipsychotics before the J Psychiatry Psychiatric Disord 2019; 3 (1): 006-013 8 commencement of the study were excluded. All psychiatric patients who attended the clinic within the study period and consented to the study were included in the study.
The height and weight of the subjects were recorded before the commencement of treatment with antipsychotics.
From this, the baseline Body Mass Index (BMI) was derived. The BMI was calculated by dividing the weight of the patient (in kilograms) by the square of his/her height (in meters). Diagnoses of their conditions were earlier made using SCAN based on the ICD 10 criteria. Each subject was given a one month appointment (for out-patients) and the BMI subsequently repeated (BMI 2 ) as well as for the subsequent two months (BMI 3 and BMI 4 ) . .
Sample size estimation
Sample size was calculated using the formula of proportions N=Z 2 pq/E 2 [11] where N=minimum sample size.
Z=1.96 (standard normal deviation for 95% confidence interval level). P=Proportion of population with condition studied (10%). Q=Complementary probability (100-p)=100-10=90. E=precision required (tolerable sampling error)=5%. The sample size was rounded off to 140.
The data was analyzed using the statistical package for social sciences (SPSS) at 5% level of significance and 95% conference interval.
Results
Out of one hundred and forty subjects (140) enlisted, 138 completed it. 
Discussion
This study showed that there was a progressive increase in the weight of the subjects on antipsychotics. This is suggested by the raised BMI changes for both typical and atypical antipsychotics from the beginning of the treatment to the end of four months when the fourth BMI was calculated. However the atypical antipsychotics, risperidone and olanzapine caused more increase in BMI compared to the typical antipsychotics, haloperidol and chlorpromazine across board. The table of ANOVA values shows that the differences in BMIs caused by the two antipsychotic types with their use over time were consistently significant. Although many-factors including sedentary lifestyle, unhealthy food habits, genetic susceptibility and antipsychotic treatment are known causes of weight gain, antipsychotic-induced weight gain remains an important concern in the management of patients treated for psychosis [12] .
The result of this study with respect to greater penchant for causing weight gain by the atypical antipsychotics compared with the typical antipsychotics is similar to results from previous studies [5, 6, 12] . Madhubhashinee et al reported that most antipsychotics cause weight gain and the risk appears to be higher with olazapine and clozapine [12] .
Reports on the socio-demographic characteristics of patients on antipsychotics are conflicting. In this study, a greater percentage of the patients are males and unemployed. This is in agreement with some studies [13, 14] .
Nevertheless, these studies also reported that most of the patients on antipsychotics have only primary or basic education contrary to the finding in our study, that a greater percentage of our study cohort had a secondary education. Methodological differences and the fact that the study was carried out in a referral centre (a tertiary hospital) may be explanatory.
Conclusion
Weight gain and obesity is a public health problem that is assuming global proportions. Considering the invaluable role antipsychotics play in the treatment of psychiatric patients, non pharmacologic interventions, such as dietary counseling, exercise programme and cognitive as well as behavioural strategies are highly recommended for patients on antipsychotics to help control the undesirable tendency towards weight gain caused by these drugs. A greater majority of our patients were schizophrenics. This is similar to reports from other studies.
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Limitation
The two groups compared were not matched for age and sex. This would have helped eliminate confounding variables to the barest minimum.
